Overcoming Cancers Resistant to HER-2 Antibodies
- 1st Edition, Volume 2 - July 17, 2024
- Latest edition
- Editor: Benjamin Bonavida
- Language: English
Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book a… Read more
Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies. There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Sections cover Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors.
This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies.
This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies.
- Provides a general summary of various sensitizing agents that can work effectively when used in combination with anti-HER2 antibodies to reverse resistance
- Offers potential underlying mechanisms by which cancer cells are either inherently resistant or become unresponsive to antibody treatment
- Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field
Cancer researchers, medical oncologists, clinicians, pharmacologists, translational investigators
1. General Introduction of Cancers responding to FDA-approved anti-HER2 antibodies (Trastuzumab)1B. Antibody Induction of Anticancer Immunity
2. Sensitization of Trastuzumab Response by the Combination with Pentuzumab
3. Sensitization by Lapatinib of Trastuzumab Resistance
4. Sensitization by Ganetespib (HSP90 inhibitor) of Trastuzumab Resistance
5. Sensitization by Paclitaxel of Trastuzumab Resistance
6. Sensitization by Celecoxib of Trastuzumab Resistance
7. Sensitization by Emantasine (T-DM1) of Trastuzumab Resistance
8. Sensitization by Anti-apoptotic Inhibitors of Trastuzumab Resistance
9. Sensitization by Kinase Inhibitors of Trastuzumab Resistance
10. Sensitization by Vinorelbine of Trastuzumab Resistance
11. Sensitization by Fulvestrant of Trastuzumab Resistance
12. Sensitization by IFF-1 Inhibitors of Trastuzumab Resistance
13. Sensitization by Liposomal Doxorubicin of Trastuzumab Resistance
14. Sensitization by Combination of Immunotherapy and Trastuzumab
15. Sensitization by Radiotherapy of Trastuzumab Resistance
16. Sensitization by Chemotherapy of Trastuzumab Resistance
17. New Development of Targeted Anti-HER-2 Antibodies
2. Sensitization of Trastuzumab Response by the Combination with Pentuzumab
3. Sensitization by Lapatinib of Trastuzumab Resistance
4. Sensitization by Ganetespib (HSP90 inhibitor) of Trastuzumab Resistance
5. Sensitization by Paclitaxel of Trastuzumab Resistance
6. Sensitization by Celecoxib of Trastuzumab Resistance
7. Sensitization by Emantasine (T-DM1) of Trastuzumab Resistance
8. Sensitization by Anti-apoptotic Inhibitors of Trastuzumab Resistance
9. Sensitization by Kinase Inhibitors of Trastuzumab Resistance
10. Sensitization by Vinorelbine of Trastuzumab Resistance
11. Sensitization by Fulvestrant of Trastuzumab Resistance
12. Sensitization by IFF-1 Inhibitors of Trastuzumab Resistance
13. Sensitization by Liposomal Doxorubicin of Trastuzumab Resistance
14. Sensitization by Combination of Immunotherapy and Trastuzumab
15. Sensitization by Radiotherapy of Trastuzumab Resistance
16. Sensitization by Chemotherapy of Trastuzumab Resistance
17. New Development of Targeted Anti-HER-2 Antibodies
- Edition: 1
- Latest edition
- Volume: 2
- Published: July 17, 2024
- Language: English
BB
Benjamin Bonavida
Dr. Benjamin Bonavida is currently a Distinguished Research Professor at the University of California, Los Angeles (UCLA). He is affiliated with the Department of Microbiology, Immunology and Molecular Genetics, UCLA David Geffen School of Medicine, and the Jonsson Comprehensive Cancer Center at UCLA. His research career, thus far, has focused on investigations in the fields of basic immunochemistry and cancer immunobiology. His research investigations have ranged from the biochemical, molecular, and genetic mechanisms of cell-mediated killing and tumor cell resistance to chemo-immuno cytotoxic drugs. The reversal of tumor cell resistance was investigated by the use of various selected sensitizing agents based on molecular mechanisms of resistance. In these investigations, there was the newly characterized dysregulated NF-kB/ Snail/YY1/RKIP/PTEN loop in many cancers that was reported to regulate cell survival, proliferation, invasion, metastasis, and resistance. Emphasis was focused on the roles of the tumor suppressor Raf kinase inhibitor protein (RKIP) and the tumor promoter Yin Yang 1 (YY1) and the role of nitric oxide (NO) as a chemo-immuno-sensitizing factor. Many of the aforementioned studies are centered on the clinical challenging features of cancer patients’ failure to respond to both conventional and targeted therapies.
Dr. Bonavida has been active in the organization of regular sequential international miniconferences that are highly focused on the roles of YY1, RKIP, and nitric oxide in cancer and their potential therapeutic applications. Several books edited or coedited have been published. In addition, he is the Series Editor of books (over 20) published by Springer/Nature: Resistance to Anti-Cancer Targeted Therapeutics. In addition, he is presently the Series Editor of Three Series published by Elsevier/Academic Press on “Cancer Sensitizing Agents for Chemotherapy,” “Sensitizing Agents for Cancer Resistance to Cell Mediated Immunotherapy,” and “Breaking Tolerance to Anti-Cancer Antibody Immunotherapy.” He is the Editor-in-Chief of the Journal Critical Reviews in Oncogenesis, Editor-in-Chief of Onco Therapeutics, and Associate Editor of “Critical Reviews in Immunology.” Dr. Bonavida has published over 500 research publications and reviews in various scientific journals of high impact.
Affiliations and expertise
Distinguished Research Professor, Department of Microbiology, Immunology and Molecular Genetics, David Ge en School of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, California, USARead Overcoming Cancers Resistant to HER-2 Antibodies on ScienceDirect